% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Woo:305651,
      author       = {S. Woo and L. Russo and S. J. Withey and A. Dehghanpour and
                      R. García-Figueiras and I. G. Schoots and G. Petralia and
                      A. Lakhani and T. Penzkofer and M. Pecoraro and C.-J. Wu and
                      J. Walz and M. Eiber and W. P. Fendler$^*$ and S. Gillessen
                      and R. Perez-Lopez and F. E. Lecouvet and T. D. Barwick and
                      A. R. Padhani},
      collaboration = {E. P. M. W. Group},
      title        = {{ESUR}: {O}pportunities for {PSMA}-{PET}/{CT} and
                      whole-body {MRI} in advanced prostate cancer.},
      journal      = {European radiology},
      volume       = {nn},
      issn         = {0938-7994},
      address      = {Heidelberg},
      publisher    = {Springer},
      reportid     = {DKFZ-2025-02283},
      pages        = {nn},
      year         = {2025},
      note         = {epub},
      abstract     = {Prostate-specific membrane antigen (PSMA) positron emission
                      tomography (PET) computed tomography (CT), and whole-body
                      magnetic resonance imaging (WB-MRI) are superior to
                      conventional CT and bone scan imaging for detecting
                      metastatic disease in patients with prostate cancer. While
                      these higher-accuracy imaging methods have already shown the
                      potential to enhance patient outcomes, a thorough
                      understanding of the relationship between the treatment
                      landscape and disease volume on conventional imaging, as
                      well as the prognostic significance of the prostate-specific
                      antigen response, is crucial for determining how they can be
                      more effectively incorporated. Prospective clinical trials
                      are required to evaluate whether PSMA-PET/CT and WB-MRI can
                      genuinely improve clinically relevant endpoints for patients
                      through precise treatment adaptations. In this paper, we
                      explore the specific opportunities of PSMA-PET/CT and WB-MRI
                      as biomarkers in multiple clinical domains, including
                      metastasis detection and staging, disease characterisation
                      and aggressiveness assessments, biopsy target selection,
                      impacts on treatment planning, evaluation of therapeutic
                      response, and theranostics. We highlight the central
                      research questions that require attention. KEY POINTS:
                      Question Can PSMA-PET/CT and WB-MRI, with their superior
                      ability to detect metastases in prostate cancer, truly
                      improve patient outcomes? Findings High-accuracy imaging
                      improves metastasis detection, staging, assessment of
                      disease aggressiveness, and enables more personalised
                      treatment planning for advanced prostate cancer patients.
                      Clinical relevance PSMA-PET/CT and WB-MRI have the potential
                      to alter the management of men with advanced prostate
                      cancer, but prospective clinical trials are needed to
                      confirm benefits for survival or quality of life before
                      recommending routine use.},
      keywords     = {Advanced prostate cancer (Other) / Metastasis (Other) /
                      Prostate specific membrane antigen positron emission
                      tomography (Other) / Whole-body magnetic resonance imaging
                      (Other)},
      cin          = {ED01},
      ddc          = {610},
      cid          = {I:(DE-He78)ED01-20160331},
      pnm          = {899 - ohne Topic (POF4-899)},
      pid          = {G:(DE-HGF)POF4-899},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:41193908},
      doi          = {10.1007/s00330-025-12089-9},
      url          = {https://inrepo02.dkfz.de/record/305651},
}